Oppenheimer Initiates Palisade Bio Inc. (PALI) at Outperform

Oppenheimer analyst Leland Gershell initiated Palisade Bio Inc. (NASDAQ: PALI) at Outperform with a price target of $8.00.

The analyst commented: "We believe PALI offers investors an attractive way to participate in the large/growing inflammatory bowel disease (IBD) space as the company's therapeutic development programs—whose approach is orthogonal to those of ABVX and EQ and backed by compelling early clinical results—move toward their first Phase 2 readout next year. We believe PALI‑2108’s appeal lies in its potential for biologic-like early symptom improvement paired with a once-daily oral profile better suited for long-term maintenance—a profile that could fill a critical gap in the evolving IBD drug landscape. With dedicated life sciences institutional holders having funded PALI through clinical reveals in both ulcerative colitis (UC) and Crohn's disease (CD), and an EV of just ~$200M, we would build a position ahead of key newsflow. Initiate w/Outperform, $8 PT."

For an analyst ratings summary and ratings history on Palisade Bio Inc. click here. For more ratings news on Palisade Bio Inc. click here.

Shares of Palisade Bio Inc. closed at $1.90 yesterday.

You May Also Be Interested In

• Benchmark on Knight Transportation (KNX) Stock: Any Pullback a Buying Opportunity
• Builders FirstSource (BLDR) PT Lowered to $100 at Benchmark, Buy Rating Maintained
• Cantor Fitzgerald Reiterates Overweight Rating on Goosehead Insurance Inc. (GSHD)